Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Cyclacel Pharmaceuticals, Inc.

Get SEC filing alerts via email and in your feed for Cyclacel Pharmaceuticals, Inc.

CYCC CYCCP

Cyclacel Pharmaceuticals, Inc.

About Cyclacel Pharmaceuticals, Inc.

Cyclacel Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing innovative cancer medicines targeting cell cycle, epigenetics, and mitosis biology. Its lead program, plogo, is a PLK1 inhibitor aimed at solid tumors and hematological malignancies. The company emphasizes targeted, oral therapies with potential for improved safety and efficacy, seeking strategic partnerships while retaining global rights to its drug candidates.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Cyclacel Pharmaceuticals, Inc.

1
1
Cyclacel Pharmaceuticals, Inc. Bio Green Med Solution Reports $778,000 Revenue in Q1 2026, Shifts Focus to Fire Safety Products

Via official filing (AI summary) | 24 days ago | 0 comments

2
1
Cyclacel Pharmaceuticals, Inc. Bio Green Med Solution Reports Revenue Surge to $747,000 Following Acquisition of Fitters Sdn. Bhd.

Via official filing (AI summary) | 2 months ago | 0 comments

3
1
Cyclacel Pharmaceuticals, Inc. Bio Green Med Solution Reports Revenue Growth and Strategic Shift to Fire Safety Products

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Cyclacel Pharmaceuticals, Inc. Cyclacel Pharmaceuticals Reports No Revenue and Strategic Changes in Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Cyclacel Pharmaceuticals, Inc. Cyclacel Pharmaceuticals Reports No Revenue and Improved Net Loss in Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Cyclacel Pharmaceuticals, Inc. Cyclacel Pharmaceuticals Reports $11.2 Million Net Loss for Fiscal Year 2024

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Cyclacel Pharmaceuticals, Inc. Cyclacel Pharmaceuticals Reports Significant Financial Challenges, Operating Loss, and Cash Flow Concerns in Latest 10-Q Filing

Via official filing (AI summary) | over 1 year ago | 0 comments